Presidio Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2006-01-01
- Employees
- 11
- Market Cap
- -
Phase 1 Study of Relative Bioavailability of PPI-668 New Tablet Versus Capsule Formulations
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-10-07
- Last Posted Date
- 2015-01-22
- Lead Sponsor
- Presidio Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02258321
- Locations
- 🇺🇸
Buffalo Clinical Research Center, Buffalo, New York, United States
Phase 1 Study of Relative Bioavailability of PPI-668 Tablet and Capsule Formulations
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-11-08
- Last Posted Date
- 2014-01-09
- Lead Sponsor
- Presidio Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01979484
- Locations
- 🇺🇸
Buffalo Clinical Research Center, Buffalo, New York, United States
A Phase 1a/1b Study of PPI-383 in Healthy Adults and Hepatitis C Patients
- First Posted Date
- 2013-08-23
- Last Posted Date
- 2015-11-26
- Lead Sponsor
- Presidio Pharmaceuticals, Inc.
- Target Recruit Count
- 114
- Registration Number
- NCT01928147
- Locations
- 🇬🇧
Investigational site, Nottingham, United Kingdom
Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-05-22
- Last Posted Date
- 2015-11-25
- Lead Sponsor
- Presidio Pharmaceuticals, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT01859962
- Locations
- 🇺🇸
Quest Clinical Research, San Francisco, California, United States
A Drug Interaction Study of the Effects of PPI-668 on the Pharmacokinetics of Midazolam and Omeprazole
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-02-08
- Last Posted Date
- 2013-03-26
- Lead Sponsor
- Presidio Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01786382
- Locations
- 🇺🇸
Spaulding Clinical Research, West Bend, Wisconsin, United States
A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1
- First Posted Date
- 2011-10-07
- Last Posted Date
- 2012-11-16
- Lead Sponsor
- Presidio Pharmaceuticals, Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT01448200
- Locations
- 🇳🇿
Investigational site, Christchurch, New Zealand
🇺🇸Investigational Site, San Antonio, Texas, United States
A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-11-24
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Presidio Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01247194
- Locations
- 🇬🇧
Local institution, London, United Kingdom
🇺🇸Local Institution, Sacramento, California, United States
© Copyright 2024. All Rights Reserved by MedPath